AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

January 18, 2024

Study Completion Date

February 12, 2024

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

AT278

Concentrated rapid acting insulin aspart

DRUG

NovoRapid

Rapid-acting insulin aspart

DRUG

Humulin R 500 UNT/ML Injectable Solution

Regular human insulin

Trial Locations (1)

Clinical Trials Unit, Medical University of Graz, Graz

All Listed Sponsors

lead

Arecor Limited

INDUSTRY